Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

Abstract

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.

Keywords: biologic agents; clinical guidelines for psoriasis; dermatology; guidelines; monoclonal antibodies; psoriasis; skin disease.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Adalimumab / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biological Products / therapeutic use*
  • Biosimilar Pharmaceuticals / therapeutic use
  • Certolizumab Pegol / therapeutic use
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Etanercept / therapeutic use
  • Evidence-Based Medicine
  • Humans
  • Infliximab / therapeutic use
  • Piperidines / therapeutic use
  • Psoriasis / drug therapy*
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Ustekinumab / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Biosimilar Pharmaceuticals
  • Dermatologic Agents
  • Piperidines
  • Pyrimidines
  • Pyrroles
  • guselkumab
  • brodalumab
  • tofacitinib
  • risankizumab
  • Infliximab
  • tildrakizumab
  • secukinumab
  • Ustekinumab
  • Adalimumab
  • Etanercept
  • Certolizumab Pegol